Skip to content

Current ratio at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
1.3×0.0×
Ardelyx logo
ArdelyxARDX
3.5×-0.6×
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
1.2×-0.8×
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
2.6×+0.4×
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
3.1×+0.5×
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
7.1×+1.0×

Other financials

Income statement

See full
Revenue$106.5M+159%
Operating income$72.6M+349%
Net income$40.8M+209%
EPS (diluted)$0.24+204%

Balance sheet

See full
Cash & equivalents$220.5M+103%
Total debt$212.4M+1,323%
Total equity-$217.1M+35.0%
Total assets$434.6M+32.8%

Cash flow

See full
Operating cash flow$5.1M-74.3%
CapEx-
Free cash flow$74.6M+390%

Valuation

See full
Market cap$632.12M+457%
Enterprise value$624M+3,024%
P/E6.2×
P/S1.8×+1.4×

Profitability

See full
Gross margin99.2%
Operating margin55.4%+38.7pp
Net margin28.3%+22.3pp
FCF margin24.7%-11.1pp

Returns & leverage

See full
Return on equity29.7%-138pp
Debt / equity-0.5×

Where this comes from

Calculated from Ironwood Pharmaceuticals’s reported figures.

Based on the most recent quarter.

The official record: Ironwood Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ironwood Pharmaceuticals's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ironwood Pharmaceuticals's current ratio?
Ironwood Pharmaceuticals (IRWD) reported current ratio of 1.4× in Q1 2026.
How has Ironwood Pharmaceuticals's current ratio changed year-over-year?
Ironwood Pharmaceuticals's current ratio decreased by 57.9% year-over-year, from 3.3× to 1.4×.
What is the long-term trend for Ironwood Pharmaceuticals's current ratio?
Over 5 years (2020 to 2025), Ironwood Pharmaceuticals's current ratio has grown at a -40.7% compound annual growth rate (CAGR), from 15.4× to 1.1×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.